Apogee Therapeutics, Inc. (APGE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$135.07-0.01%
Close 2026-09-02 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · APGE
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | |
|---|---|---|---|---|---|
| Operating Expenses & Income | |||||
| R&D Expenses | 240.7 | 214.7 | 167.9 | 68.4 | — |
| Operating Income | (328.1) | (285.6) | (216.9) | (93.0) | — |
| Earnings from Continuing Operations | |||||
| Interest & Investment Income | 35.6 | 30.0 | 34.7 | 9.0 | — |
| EBT, Incl. Unusual Items | (294.1) | (255.6) | (182.1) | (84.0) | — |
| Income Tax Expense | 0.3 | 0.3 | 0.0 | 0.0 | — |
| Net Income | |||||
| Net Income | (294.4) | (255.8) | (182.1) | (84.0) | — |
| Per Share | |||||
| Basic EPS | (3.90) | (4.22) | (3.30) | (3.36) | — |
| Diluted EPS | (3.90) | (4.22) | (3.30) | (3.36) | — |
| Basic Weighted Avg Shares | 75.4 | 60.7 | 55.2 | 25.0 | — |
| Diluted Weighted Avg Shares | 75.4 | 60.7 | 55.2 | 25.0 | — |
| Supplemental | |||||
| EBIT | (328.1) | (285.6) | (216.9) | (93.0) | — |
| Effective Tax Rate | -0.1% | — | — | 0.0% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.